The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAP-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject.

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAP-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject.

The present disclosure provides compounds of Formula (VIIb) and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer. ##STR00001##

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAP-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject.

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAP-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject.

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAp-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject.

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAp-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject.

The present invention relates to an electrolyte composition (A) containing (i) at least one aprotic organic solvent; (ii) at least one conducting salt; (iii) at least one compound of formula (I) and (iv) optionally at least one further additive. ##STR00001##

The present invention relates to substituted 2-[2-halogenalkyl-4-(phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds of formula I as defined in the description, and the N-oxides, and salts thereof, their preparation and intermediates for preparing them. The invention also relates to the use of these compounds for combating harmful fungi and seed coated with at least one such compound and also to compositions comprising at least one such compound.

A process for at least partially reactivating the catalytic activity of at least a partially deactivated catalyst following a reaction cycle, the catalyst having been used in a catalytic reaction process for hydrogenating an aromatic epoxide to produce a hydrogenated aliphatic epoxide; said process including contacting the at least partially deactivated catalyst with an oxygen-containing source at a temperature of less than about 100 C. and in the presence of a reactivation solvent for a pre-determined period of time sufficient to at least partially re-oxidize and reactivate the catalyst for further use; and a catalytic reaction process for hydrogenating an aromatic epoxide to produce a hydrogenated aliphatic epoxide including the above reactivating process step; and optionally including a step for washing the deactivated catalyst with a solvent prior to re-oxidizing the deactivated catalyst.